Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ICMT | O60725 | 14/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423426 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL8025173 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL2818645 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL5433147 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL5274733 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL1648111 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL4024890 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL2818639 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL1648108 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL1762100 | 0.99 | MAPT (0.97) | MAPTALDH1A1ICMTMEN1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118142070-A | Combined anti-aging method for improving skin quality and skin age | 厦门起点生物药业有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-113440435-B | Preparation method of skin anti-aging composition | 珀莱雅化妆品股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-3600266-B1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF CARDIOVASCULAR CALCIFICATION | INST NAT SANTE RECH MED (FR) | 2022-07-27 | — | — | EP | claimed |
| CN-113440435-A | Preparation method of skin anti-aging composition | 珀莱雅化妆品股份有限公司 | 2021-09-28 | — | — | CN | claimed |
| US-20170157170-A1 | COMPOSITIONS CONTAINING POLYMERIC SULFUR AND USES THEREOF | KENVUE BRANDS LLC | 2017-06-08 | — | — | US | claimed |
| EP-3175888-A1 | COMPOSITIONS CONTAINING POLYMERIC SULFUR AND USES THEREOF | Johnson & Johnson Consumer Inc. (US) | 2017-06-07 | — | — | EP | claimed |
| US-9629856-B2 | Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds | ANTEIS SA (CH) | 2017-04-25 | — | — | US | claimed |
| US-20160243011-A1 | Formulations Comprising Idebenone, N-Acetyl-S-Farnesyl-L-Cysteine and Ergothioneine and Uses Thereof | REVLON CONSUMER PRODUCTS CORPORATION | 2016-08-25 | — | — | US | claimed |
| EP-2895159-A2 | FORMULATIONS COMPRISING IDEBENONE, N-ACETYL-S-FARNESYL-L-CYSTEINE AND ERGOTHIONEINE AND USES THEREOF | ELIZABETH ARDEN INC. (US) | 2015-07-22 | — | — | EP | claimed |
| WO-2014043230-A2 | FORMULATIONS COMPRISING IDEBENONE, N-ACETYL-S-FARNESYL-L-CYSTEINE AND ERGOTHIONEINE AND USES THEREOF | ELIZABETH ARDEN, INC. (US) | 2014-03-20 | — | — | WO | claimed |
| WO-2006135894-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2006-12-21 | — | — | WO | claimed |
| WO-2005123103-A1 | TOPICAL COMPOSITIONS AND METHODS FOR EPITHELIAL-RELATED CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2005-12-29 | — | — | WO | claimed |
| US-20050277694-A1 | Topical compositions and methods for epithelial-related conditions | SIGNUM BIOSCIENCES, INC. (US) | 2005-12-15 | — | — | US | claimed |
| US-20040152073-A1 | Therapeutic targets for treatment of HCV infections, methods of treating HCV infections and compounds useful therefor | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2004-08-05 | — | — | US | claimed |
| US-20040138446-A1 | Biotin derivatives, methods for making same and uses thereof as vectors | CNRS/EPST (FR) | 2004-07-15 | — | — | US | claimed |
| EP-1347985-A2 | BIOTIN DERIVATIVES, METHODS FOR MAKING SAME AND USES THEREOF AS VECTORS | MILLEGEN (SARL) (FR) | 2003-10-01 | — | — | EP | claimed |
| US-20030180719-A1 | Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-25 | — | — | US | claimed |
| WO-2002042311-A2 | BIOTIN DERIVATIVES, METHODS FOR MAKING SAME AND USES THEREOF AS VECTORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M) (FR) | 2002-05-30 | — | — | WO | claimed |
| US-6015877-A | ANTICARCINOGENIC AGENT WHICH INHIBITS ENDOPROTEASE ACTIVITY DIRECTED AGAINST SPECIFIC CYSTEINE CONTAINING CARBOXY TERMINAL MOTIF FOUND IN RAS PROTEINS AND OTHER SIGNAL TRANSDUCING G PROTEINS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-01-18 | — | — | US | claimed |
| US-5202456-A | Anticarcinogenic agents; methylating transferase inhibitors; farnesyl or geranyl sulfur-, oxygen or selenium-containing derivatives | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1993-04-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277694-A1 | Topical compositions and methods for epithelial-related conditions | KRT18, CUTA, SERPINB1 | MAPT 2316/4885ALDH1A1 2524/4885ICMT 4670/4885 |
| US-20160243011-A1 | Formulations Comprising Idebenone, N-Acetyl-S-Farnesyl-L-Cysteine and Ergothioneine and Uses Thereof | NQO1, KEAP1, NDUFB10 | MAPT 1362/4885ALDH1A1 583/4885ICMT 80/4885 |
| US-20040138446-A1 | Biotin derivatives, methods for making same and uses thereof as vectors | HLCS, BTD, CYC1 | MAPT 4517/4885ALDH1A1 812/4885ICMT 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.